RATIONALE: The a2A-noradrenergic agonist guanfacine can decreases stress-induced smoking in female, but not male, human smokers. It is not known whether these effects are due to effects on mood regulation and/or result from nicotinic-cholinergic interactions. OBJECTIVES: The objective of the study was to determine whether there are sex differences in the effect of guanfacine in tests of anxiolytic and antidepressant efficacy in mice at baseline and in a hypercholinergic model of depression induced by the acetylcholinesterase inhibitor physostigmine. METHODS: The effects of guanfacine were measured in the light/dark box, tail suspension, and the forced swim test in female and male C57BL/6J mice. In parallel, electrophysiological properties were evaluated in the prefrontal cortex, a critical brain region involved in stress responses. c-fos immunoreactivity was measured in other brain regions known to regulate mood. RESULTS: Despite a baseline sex difference in behavior in the forced swim test (female mice were more immobile), guanfacine had similar, dose-dependent, antidepressant-like effects in mice of both sexes (optimal dose, 0.15 mg/kg). An antidepressant-like effect of guanfacine was also observed following pre-treatment with physostigmine. A sex difference in the paired-pulse ratio in the prefrontal cortex (PFC) (male, 1.4; female, 2.1) was observed at baseline that was normalized by guanfacine. Other brain areas involved in cholinergic control of depression-like behaviors, including the basolateral amygdala and lateral septum, showed sex-specific changes in c-fos expression. CONCLUSIONS: Guanfacine has a robust antidepressant-like effect and can reverse a depression-like state induced by increased acetylcholine (ACh) signaling. These data suggest that different brain areas are recruited in female and male mice, despite similar behavioral responses to guanfacine.
RATIONALE: The a2A-noradrenergic agonist guanfacine can decreases stress-induced smoking in female, but not male, human smokers. It is not known whether these effects are due to effects on mood regulation and/or result from nicotinic-cholinergic interactions. OBJECTIVES: The objective of the study was to determine whether there are sex differences in the effect of guanfacine in tests of anxiolytic and antidepressant efficacy in mice at baseline and in a hypercholinergic model of depression induced by the acetylcholinesterase inhibitor physostigmine. METHODS: The effects of guanfacine were measured in the light/dark box, tail suspension, and the forced swim test in female and male C57BL/6J mice. In parallel, electrophysiological properties were evaluated in the prefrontal cortex, a critical brain region involved in stress responses. c-fos immunoreactivity was measured in other brain regions known to regulate mood. RESULTS: Despite a baseline sex difference in behavior in the forced swim test (female mice were more immobile), guanfacine had similar, dose-dependent, antidepressant-like effects in mice of both sexes (optimal dose, 0.15 mg/kg). An antidepressant-like effect of guanfacine was also observed following pre-treatment with physostigmine. A sex difference in the paired-pulse ratio in the prefrontal cortex (PFC) (male, 1.4; female, 2.1) was observed at baseline that was normalized by guanfacine. Other brain areas involved in cholinergic control of depression-like behaviors, including the basolateral amygdala and lateral septum, showed sex-specific changes in c-fos expression. CONCLUSIONS:Guanfacine has a robust antidepressant-like effect and can reverse a depression-like state induced by increased acetylcholine (ACh) signaling. These data suggest that different brain areas are recruited in female and male mice, despite similar behavioral responses to guanfacine.
Authors: Avis Brennan Hains; Mai Anh T Vu; Paul K Maciejewski; Christopher H van Dyck; Melissa Gottron; Amy F T Arnsten Journal: Proc Natl Acad Sci U S A Date: 2009-09-11 Impact factor: 11.205
Authors: Kurt P Schulz; Suzanne M Clerkin; Jin Fan; Jeffrey M Halperin; Jeffrey H Newcorn Journal: Psychopharmacology (Berl) Date: 2012-10-20 Impact factor: 4.530
Authors: Angela M Lee; Cali A Calarco; Sherry A McKee; Yann S Mineur; Marina R Picciotto Journal: Genes Brain Behav Date: 2019-08-13 Impact factor: 3.449
Authors: Nicholas A Harris; Austin T Isaac; Anne Günther; Kevin Merkel; James Melchior; Michelle Xu; Eghosa Eguakun; Rafael Perez; Brett P Nabit; Stephanie Flavin; Ralf Gilsbach; Brian Shonesy; Lutz Hein; Ted Abel; Arnd Baumann; Robert Matthews; Samuel W Centanni; Danny G Winder Journal: J Neurosci Date: 2018-08-27 Impact factor: 6.167
Authors: Zack Zurawski; Analisa D Thompson Gray; Lillian J Brady; Brian Page; Emily Church; Nicholas A Harris; Michael R Dohn; Yun Young Yim; Karren Hyde; Douglas P Mortlock; Carrie K Jones; Danny G Winder; Simon Alford; Heidi E Hamm Journal: Sci Signal Date: 2019-02-19 Impact factor: 8.192
Authors: Yann S Mineur; Vernon Garcia-Rivas; Merrilee A Thomas; Alexa R Soares; Sherry A McKee; Marina R Picciotto Journal: Psychopharmacology (Berl) Date: 2022-03-31 Impact factor: 4.530
Authors: Yann S Mineur; Emma L Cahuzac; Tenna N Mose; Matthew P Bentham; Margreet E Plantenga; David C Thompson; Marina R Picciotto Journal: Neuropsychopharmacology Date: 2018-02-22 Impact factor: 7.853